Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Fineline Cube Jul 2, 2026
Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Fineline Cube Jul 2, 2026
Company Drug

GSK’s Shingrix Prefilled Syringe Accepted for FDA Review

Fineline Cube Jan 13, 2025

UK-headquartered GlaxoSmithKline (GSK; NYSE: GSK) has announced that a market filing for a prefilled syringe...

Policy / Regulatory

NHSA Launches Nationwide Self-Inspection Campaign on Medical Insurance Fund Usage

Fineline Cube Jan 13, 2025

China’s National Healthcare Security Administration (NHSA) released a notification last weekend, mandating designated medical institutions...

Policy / Regulatory

China’s NHSA Implements New Regulations for Medical Insurance Payment Qualifications

Fineline Cube Jan 13, 2025

China’s National Healthcare Security Administration (NHSA) has released the “Regulations on the Management of Medical...

Company

Shenzhen Oculgen Secures Over RMB 100 Million in Series A Funding

Fineline Cube Jan 11, 2025

Shenzhen Oculgen Biomedical Technology Co., Ltd. has successfully completed a Series A financing round, raising...

Company Drug

Fosun Pharmaceutical’s FCN-437c Accepted for NMPA Review for Breast Cancer Treatment

Fineline Cube Jan 11, 2025

Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) has announced that another market approval...

Company Drug

Hengrui’s SHR4640 Accepted for NMPA Review for Gout and Hyperuricemia Treatment

Fineline Cube Jan 11, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that a market filing for...

Company Deals

Keymed Biosciences Licenses CM313 to Timberlyne Therapeutics for Global Development

Fineline Cube Jan 11, 2025

China-based Keymed Biosciences Inc. (HKG: 2162) has entered into a licensing agreement with US firm...

Company Deals

Biocytogen and SOTIO Biotech Partner on Colorectal Cancer ADC Candidate SOT109

Fineline Cube Jan 11, 2025

China-based Biocytogen (HKG: 2315) has announced an option and licensing agreement with SOTIO Biotech, allowing...

Company Deals

Novo Nordisk and Valo Health Expand Partnership to Develop Treatments for Obesity and Diabetes

Fineline Cube Jan 11, 2025

Partners Novo Nordisk (NYSE: NVO) and Valo Health have announced an expanded partnership, aiming to...

Company Deals

Immunochina Pharmaceuticals Raises Series E Funding for CAR-T Therapy IM19

Fineline Cube Jan 11, 2025

Beijing-based biotech Immunochina Pharmaceuticals has reportedly raised “hundreds of millions” of renminbi in a Series...

Company Drug

Sinogen’s SalMet-Vec Receives FDA Orphan Drug Designation for Pancreatic Cancer

Fineline Cube Jan 10, 2025

China’s oncology specialist Guangzhou Sinogen Pharmaceutical Co., Ltd. has announced receiving Orphan Drug Designation (ODD)...

Legal / IP

SynCardia’s Next-Generation Artificial Heart Granted Patent in China

Fineline Cube Jan 10, 2025

US-based SynCardia Systems, LLC., a global leader in total artificial heart technology, has announced that...

Company Deals

Zai Lab and MediLink Therapeutics Partner to Develop LRRC15 ADC Drug ZL-6201 for Solid Tumors

Fineline Cube Jan 10, 2025

On January 10, Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced a new strategic cooperation...

Company Deals

Danaher Corporation Partners with Innovaccer to Enhance Healthcare AI Solutions

Fineline Cube Jan 10, 2025

US-based science and tech services giant Danaher Corporation (NYSE: DHR) has announced an investment partnership...

Company Drug

Sanofi’s Sarclisa Meets Co-Primary Endpoints in Phase III IRAKLIA Study for Multiple Myeloma

Fineline Cube Jan 10, 2025

French pharmaceutical giant Sanofi (NASDAQ: SNY, EPA: SAN) has announced that the Phase III IRAKLIA...

Company Drug

FDA Grants Priority Review to Johnson & Johnson’s Nipocalimab for Myasthenia Gravis

Fineline Cube Jan 10, 2025

US-based Johnson & Johnson (J&J, NYSE: JNJ) has announced that the US FDA has granted...

Company Deals

Boehringer Ingelheim Licenses ADC Technology from Synaffix to Boost Portfolio

Fineline Cube Jan 10, 2025

German giant Boehringer Ingelheim has announced the licensing of antibody drug conjugate (ADC) technology from...

Company Deals

Alchemab Therapeutics Partners with Eli Lilly to Discover ALS Treatments

Fineline Cube Jan 10, 2025

UK-based Alchemab Therapeutics has formed a strategic partnership with US major Eli Lilly & Co....

Company Medical Device

Roche Gains FDA 510(k) Clearance for Roche Digital Pathology Dx with VENTANA DP 600

Fineline Cube Jan 10, 2025

Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced an additional 510(k) clearance from the...

Company Deals

TCMTech Files for IPO on Hong Kong Stock Exchange, Showcasing TCM AI Leadership

Fineline Cube Jan 10, 2025

China-based TCMTech Inc., recognized as the largest artificial intelligence (AI) empowered traditional Chinese medicine (TCM)...

Posts pagination

1 … 253 254 255 … 690

Recent updates

  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
  • Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy
  • Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched
  • TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations
  • TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Company Drug

TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.